Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question | Zendy

Cavallari L H | Zendy; Nutescu E A | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question

Author(s) -

Cavallari L H,

Nutescu E A

Publication year - 2014

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2014.78

Subject(s) - warfarin , pharmacogenetics , dosing , clinical pharmacology , vkorc1 , medicine , genotype , cyp2c9 , clinical trial , pharmacology , biology , atrial fibrillation , genetics , cytochrome p450 , metabolism , gene

Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype‐guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics. Clinical Pharmacology & Therapeutics (2014); 96 1, 22–24. doi: 10.1038/clpt.2014.78

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research